Technology & Software Global On demand · 24-48h

Global Microarray-based Non-Invasive Prenatal Testing Market Strategic Research Report

Name: Global Microarray-based Non-Invasive Prenatal Testing Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Microarray-based Non-Invasive Prenatal Testing Market…

$3,500 USD

Strategic Research Report

Global Microarray-based Non-Invasive Prenatal Testing Market

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Trisomy Detection, Microdeletion Syndromes, Other

By Application: Hospitals & Clinics, Independent Laboratories

Key Players: Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, Laboratory Corporation of America, Myriad Genetics, Natera, PerkinElmer Inc, Quest Diagnostics, Sequenom

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2024 · forecast to 2032

Length: 117 pages

Übersicht

Scope of the Report

The global Microarray-based Non-Invasive Prenatal Testing market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

For expectant mothers, microarray-based non-invasive prenatal testing (NIPT) provides a secure and educational screening choice. To determine the likelihood of chromosomal abnormalities in the foetus, it examines cell-free foetal DNA that is circulating in the mother's blood. In contrast to conventional techniques that may result in miscarriage, NIPT is a blood test. With a detection rate for Down syndrome that is above 99%, this extremely reliable test yields findings in less than a week. In comparison to earlier techniques, it can even test for a wider spectrum of disorders. However, NIPT is only a screening tool and not a conclusive diagnosis. It could require more testing to be confirmed. It might not be appropriate for all pregnancies, and the cost and insurance coverage can differ.

Global key Microarray-based Non-Invasive Prenatal Testing players cover Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, etc.

This report presents a comprehensive overview of the global Microarray-based Non-Invasive Prenatal Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Trisomy Detection
Microdeletion Syndromes
Other

Segment by Application

Hospitals & Clinics
Independent Laboratories

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Microarray-based Non-Invasive Prenatal Testing market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Hospitals & Clinics, Independent Laboratories evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type

Trisomy DetectionMicrodeletion SyndromesOther

By Application

Hospitals & ClinicsIndependent Laboratories

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Trisomy Detection
3.1.3 Microdeletion Syndromes
3.1.4 Other
3.1.5 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Hospitals & Clinics
4.1.3 Independent Laboratories
4.1.4 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Agilent Technologies
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Ariosa Diagnostics (Roche)
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 BGI Group
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 Eurofins LifeCodexx GmbH
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Illumina
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 Laboratory Corporation of America
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 Myriad Genetics
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 Natera
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 PerkinElmer Inc
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Quest Diagnostics
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 Sequenom
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What does the Microarray-based Non-Invasive Prenatal Testing market cover?

What are the main segments of the Microarray-based Non-Invasive Prenatal Testing market by type?

By type, the market is segmented into Trisomy Detection, Microdeletion Syndromes and Other.

Which applications drive demand in the Microarray-based Non-Invasive Prenatal Testing market?

Key applications covered include Hospitals & Clinics and Independent Laboratories.

Who are the key players in the Microarray-based Non-Invasive Prenatal Testing market?

Key players profiled include Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, Laboratory Corporation of America, Myriad Genetics and Natera, among 11 companies covered in total.

Which regions and countries are covered for Microarray-based Non-Invasive Prenatal Testing?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Microarray-based Non-Invasive Prenatal Testing market report?

The report is intended for manufacturers and solution providers, distributors and end users in Hospitals & Clinics and Independent Laboratories, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Microarray-based Non-Invasive Prenatal Testing market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.